Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Hold” by Brokerages

Pacira BioSciences, Inc. (NASDAQ:PCRX) has received a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $22.78.

Several brokerages have weighed in on PCRX. Barclays reduced their price objective on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Finally, Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 13th.

Pacira BioSciences Stock Down 0.4 %

PCRX opened at $27.13 on Thursday. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $31.67. The company’s 50-day moving average price is $21.56 and its two-hundred day moving average price is $18.00. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -13.36 and a beta of 0.80. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently modified their holdings of PCRX. Caitlin John LLC lifted its stake in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares in the last quarter. CWM LLC increased its position in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the last quarter. Finally, Virtus Investment Advisers Inc. purchased a new stake in Pacira BioSciences in the third quarter valued at approximately $98,000. 99.73% of the stock is currently owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.